CVE-2024-1180

TP-Link Omada ER605 Access Control Command Injection Remote Code Execution Vulnerability

Description

TP-Link Omada ER605 Access Control Command Injection Remote Code Execution Vulnerability. This vulnerability allows network-adjacent attackers to execute arbitrary code on affected installations of TP-Link Omada ER605. Authentication is required to exploit this vulnerability. The specific issue exists within the handling of the name field in the access control user interface. The issue results from the lack of proper validation of a user-supplied string before using it to execute a system call. An attacker can leverage this vulnerability to execute code in the context of root. Was ZDI-CAN-22227.

Category

6.8
CVSS
Severity: Medium
CVSS 3.0 •
EPSS 0.43%
Affected: TP-Link Omada ER605
Published at:
Updated at:

References

Link Tags
https://www.zerodayinitiative.com/advisories/ZDI-24-086/

Frequently Asked Questions

What is the severity of CVE-2024-1180?
CVE-2024-1180 has been scored as a medium severity vulnerability.
How to fix CVE-2024-1180?
To fix CVE-2024-1180, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2024-1180 being actively exploited in the wild?
As for now, there are no information to confirm that CVE-2024-1180 is being actively exploited. According to its EPSS score, there is a ~0% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
What software or system is affected by CVE-2024-1180?
CVE-2024-1180 affects TP-Link Omada ER605.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.